The Role of Weight Loss (WL) as On-Tretament Predictive Factor for SVR in the Treatment of Chronic Hepatitis C (CHC) Patients with Peginterferon alfa–2A (PEG) and Ribavirin (RBV)
T Witthöft, P Buggisch, D Hüppe, R Heyne, C John, B Möller, G Moog, A Schober, W Schiffelholz, A Baumgarten, G Teuber, T Lutz, A Stoehr, U Alshuth, S Mauss · Zeitschrift für Gastroenterologie · 2012 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aim: It is helpful to know different baseline and on-treatment factors that help in decision making for intensifying or facilitating therapy. Here we analysed the value of WL during PEG/RBV. Methods: From 2008–2011, 3810 pts were fully documented in a noninterventional study of bng and Roche. Of them 1100 were treated according to consensus guidelines (GT–1/4/5/6 for 48±4 wks, GT–2/3 for 24±2 wks). Pts with HIV or HBV coinfection were excluded. Descriptive, univariate and multivariate analyses were performed to determine factors associated with SVR. Results: Demographics: 59.7% male, 44.2 yrs of age, BMI 25.5kg/…
